Research Article
Effects of Fisetin on Allergic Contact Dermatitis via Regulating the Balance of Th17/Treg in Mice

Bocui Song,1 Xue Shen,2 Shuang Zhang,3 Rui Zhao,1 Yanhong Wang,4 Mengmeng Jiang,1 Min Liu,1 Qian Chen,2 Yuqi Li,2 Baolei Huang,1 Chenghao Jin,5 and Chunyu Tong5

1Department of Pharmaceutical Engineering, College of Life Science & Technology, Heilongjiang Bayi Agricultural University, Daqing, 163319 Heilongjiang Province, China
2Molecular Mechanism of Disease & Research and Development of Bioactive Substances, College of Life Science & Technology, Heilongjiang Bayi Agricultural University, Daqing, 163319 Heilongjiang Province, China
3Animal Husbandry and Veterinary Station of Yongji Economic Development Zone, Jilin, 132200 Jilin Province, China
4Department of Biological Engineering, College of Life Science & Technology, Heilongjiang Bayi Agricultural University, Daqing, 163319 Heilongjiang Province, China
5Department of Biological Science, College of Life Science & Technology, Heilongjiang Bayi Agricultural University, Daqing, 163319 Heilongjiang Province, China

Correspondence should be addressed to Chenghao Jin; jin2633204897@163.com and Chunyu Tong; tongchunyu@byau.edu.cn

Received 28 February 2022; Revised 16 March 2022; Accepted 21 March 2022; Published 9 April 2022

Academic Editor: Min Tang

Copyright © 2022 Bocui Song et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Allergic contact dermatitis (ACD) is a form of chronic cutaneous inflammatory disease of immunological origin that has adverse impacts on patient quality of life, underscoring the need for the development of safe and effective therapeutic agents to treat affected individuals. Fisetin is a Chinese herbal preparation that reportedly exhibits antitumor, antioxidant, antimicrobial, anticoagulatory, and antimalarial activity. In the current report, the immunomodulatory activity of fisetin was appraised by assessing its impact on balance between regulatory T (Treg) and Th17 cells in an ACD model.

Methods. BALB/c mice (n = 60) were randomized into control, ACD model, CTX positive control (20 mg/kg), and fisetin treatment groups (three dose levels: 2, 4, or 8 mg/kg). ACD induction was achieved by sensitizing mice on the shaved ventral abdomen via the application of 5% DNFB (50 μL) on days 1 and 2, followed by rechallenge in the right ear with 5% DNFB (20 μL) on day 5. Beginning on day 1, immunized mice were intraperitoneally injected with the appropriate fisetin dose (in saline) once per day for 7 days. On day 7, ear swelling, transcription factor expression, Th17/Treg cell populations, and cytokine production were assessed in vivo.

Results. Fisetin treatment significantly suppressed ear swelling and associated inflammatory cell infiltration, besides reducing the production of Th17 cytokines (IL-17, TNF-α, and IL-6) and the expression of the Th17 lineage transcription factor RORyt while simultaneously enhancing Treg-specific cytokine production (TGF-β and IL-10) and the expression of the Treg lineage transcription factor Foxp3, thereby restoring the Th17/Treg cell balance in ACD mice. Conclusions. These data indicate that fisetin exhibits immunomodulatory activity and can alter the Th17/Treg cell balance, highlighting its potential value as a treatment drug for ACD.

1. Introduction

Allergic contact dermatitis (ACD) is a form of T cell-mediated inflammatory skin disease in which sensitized T cells react to particular antigens and release inflammatory cytokines, thereby promoting localized inflammatory cell infiltration, tissue degeneration, and necrosis [1–3]. Many reports have demonstrated a link between ACD incidence and an imbalance between the Th1 and Th2 CD4+ T cell subsets. Recent work further suggests that Th17 and regulatory T (Treg) cells can also modulate immune homeostasis [4–6].
ACD patients often experience symptoms such as pruritus, edema, erythema, and coalescing edematous papules [7, 8]. The World Health Organization estimates that 15% of the global population is affected by ACD. Topical treatments for ACD include nonsteroidal anti-inflammatory drugs, H1 receptor antagonists, and glucocorticosteroids. These drugs exhibit a wide range of side effects when used at high doses, however [9–11], underscoring the need for the development of novel ACD treatments of fewer side effects.

Herbal medicines have long been used to treat diseases. Given the wide distribution of herbal resources, their inexpensive nature, and the low levels of toxicity associated with herbal medicine-based therapies, they hold great promise as advantageous means of treating disease. Fisetin (3,7,3,4-tetrahydroxyflavone) is a flavonoid present within a range of fruits and vegetables including apples, onions, grapes, strawberries, and cucumbers at doses of 2-160 μg/g [12, 13]. Fisetin has previously been shown to inhibit monoamine oxidase activity associated with the norepinephrine and serotonin systems, thus exerting antidepressant activity [14–16]. It has also been reported to stimulate cell signaling, thereby improving long-term memory [17]. Moreover, fisetin can alter signal transduction, suppress tumor cell proliferation, migration, and invasion, and promote apoptotic tumor cell death [18–22]. It also exhibits hepatoprotective and reperative efficacy in the context of hepatitis-related liver damage [23, 24], while also mitigating aflatoxin cytotoxicity [25]. The chemical structure of fisetin is as indicated.

We have previously found that fisetin can suppress the Th1/Th2 cell balance in vitro and in vivo in addition to suppressing IL-17 production, suggesting that this compound has the potential to modulate Th17 cell functionality. To more fully explore the immunopharmacological activity of fisetin, we herein assessed its ability to modulate the Th17/Treg balance and to thereby attenuate disease severity in a murine model of DNFB-induced ACD.

2. Materials and Methods

2.1. Chemicals and Reagents. Fisetin (>98% pure, catalog number: 528483, Figure 1) was obtained from Sigma-Aldrich and diluted in culture media containing 0.1% DMSO, sterile filtered, and stored at 4°C prior to utilization. An equivalent DMSO concentration was used for all control animals. Cyclophosphamide (CTX) and 2,4-dinitrofluorobenzene (DNFB) were procured from Sigma (MO, USA). RPMI-1640 was from HyClone (Logan, UT). Moreover, BioLegend (CA, USA) supplied IL-6, IL-17, TGF-β, TNF-α, and IL-10 ELISA kits. PE-anti-IL-17A, FITC-anti-CD4, APC-anti-CD25, and PE-anti-Foxp3 were from BD Pharmingen.

2.2. Animals. BALB/c mice (16–18 g, 6–8 weeks old, 50% male, 50% female) were acquired from the Jilin University Experimental Animal Center and housed in microisolator cages with free water and food accessibility. The Animal Welfare and Research Ethics Committee at Heilongjiang Bayi Agriculture University approved all animal studies.

2.3. ACD Model Establishment. To induce ACD, the ventral abdomen of mice was shaved and sensitized with 5% DNFB (50 μL; acetone : olive oil = 4 : 1) on days first and second. After five days, mice were then challenged through painting both the outer and inner surfaces of the right ear with 10 μL of 5% DNFB (acetone : olive = 4 : 1), while the left ear was painted with an equivalent volume of a control acetone and olive oil (4:1) mixture. Ear swelling at 48 h after the second challenge was then assessed by weighing ear patches from both ears prepared with an 8 mm punch and comparing these relative weights.

2.4. Drug Treatment. BALB/c mice (n = 60) were randomized into six groups (10/group) including a control group, an ACD model group, a positive control CTX (20 mg/kg) group, and three fisetin groups (2, 4, and 8 mg/kg). Treatments were intraperitoneally administered to mice once per day for 7 days, with control animals being administered an equivalent volume of 0.1% DMSO.

2.5. Ear Swelling Analyses. At 24 h post-DNFB stimulation, both ears were punched and the removed tissue was weighed as a means of quantifying ear swelling in these animals as a readout for the magnitude of ACD reactions as follows: 24 h after the mice were finally stimulated with DNFB for allergy, the left and right ears of the mice were punched and weighed to calculate the ear swelling of the mice, which reflects the reaction intensity of ACD. Formula: edema rate (mg) = \( W_{\text{right ear}} - W_{\text{left ear}} \), where edema rate corresponds to ear swelling, \( W_{\text{right ear}} \) corresponds to right ear weight (mg), and \( W_{\text{left ear}} \) corresponds to left ear weight (mg).

2.6. Histological Observations. At 24 h post-DNFB stimulation, the left and right auricles were collected using clean scissors from mice in each group and fixed for 24 h in 10% formalin. These tissues were then dehydrated, inserted in paraffin, and cut into segments. Following deparaffinization, hematoxylin-eosin staining was performed and tissues were imaged via microscopy to identify appropriate representative regions for analysis.

2.7. Flow Cytometry. On day 7 of the study period, 1 × 10^6 splenocytes were rimed with PBS, after which red blood cells were lyzed employing ACK lysis buffer and the left lymphocytes were suspended in RPMI-1640 including 10% FBS. Th17 and Treg cells were analyzed through incubating these cells for 4 h with ConA and then staining them with PE-anti-IL-17A, FITC-anti-CD4, APC-anti-CD25, and PE-anti-Foxp3 followed by subsequent flow cytometry-based quantification.
2.8. Analysis of Foxp3 and RORγt mRNA Level Expression. TRIzol was employed for the extraction of total RNA from splenocytes, following which a RevertAid first-strand cDNA synthesis kit and random primers were used to synthesize cDNA. Then, SYBR® Premix Ex Taq™ II was used to amplify the Foxp3, RORγt, and β-actin in a 25 μL reaction volume, with β-actin serving as a normalization control. Primer sequences employed in this research are compiled in Table 1.

2.9. ELISAs. Capture antibodies were incubated in 96-well plates overnight at 4°C, after which plates were washed and 100 μL of appropriate blood samples was added to appropriate wells, succeeded by a 2 h incubation at 37°C. Plates were then rinsed 4 times, succeeded by the addition of 100 μL of secondary antibody (1:200) at 37°C for 1 h. Plates were then rinsed again and incubated by implementing 100 μL of horseradish peroxidase (HRP; 1:1000) per well at 37°C for 30 min. Plates were subsequently rinsed 5 times using wash buffer, and 100 μL of TMB substrate was then added per well. Following a 15 min incubation at 25°C while protected from light, reactions were terminated via the addition of 2 M H₂SO₄. Plates were then allowed to stand for 5 min, after which a microplate reader was used to assess OD values at 450 nm. A standard curve was then used to measure IL-17, IL-10, IL-6, and TGF-β content in each sample.

2.10. Statistical Analyses. Data are means ± standard deviations (SD) and were compared via Student’s t-test employing SPSS 13.0. P < 0.05 was the significance threshold (n = 3).

3. Results

3.1. Fisetin Suppresses Ear Swelling in a Murine ACD Model. Relative to the control group, ear swelling in ACD model mice was substantially enhanced (P < 0.01; Figure 2(a)), while following the intraperitoneal injection of fisetin, analyses revealed that a low fisetin dose significantly suppressed ear swelling in these animals (P < 0.05), with medium and high fisetin doses having an even more pronounced inhibitory effect of such swelling in a dose-dependent manner (P < 0.01). Low-dose fisetin treatment was more efficacious than treatment with the clinical immunosuppressive drug CTX.

3.2. Fisetin Normalizes Histopathological Findings in ACD Model Mice. To more fully evaluate the impact of fisetin treatment, ear tissue sections from treated mice were subjected to H&E staining. Relative to control animals, those in the ACD model group demonstrated increased inflammatory cell infiltration and swelling following DNFB challenge, consistent with successful ACD model establishment (Figure 2(b)). However, fisetin treatment significantly reduced such inflammatory infiltration relative to the ACD and CTX groups, further confirming the ability of fisetin to suppress ACD-related ear swelling.

3.3. Fisetin Modulates the Th17/Treg Balance in ACD Model Mice. The impact on fisetin treatment of Th17 and Treg cell populations in ACD model mice was next assessed (Table 2). Relative to control animals, ACD model mice exhibited significant increases in Th17 cells and substantial reductions in Treg cells (P < 0.01), whereas fisetin and CTX treatment reversed these alterations (P < 0.05 or P < 0.01). The obtained outcomes define that fisetin is capable of regulating the Th17/Treg cell balance.

3.4. Fisetin Modulates RORγt and Foxp3 mRNA Expression in ACD Model Mice. Next, RT-PCR was employed to appraise relative RORγt and Fopx3 expression in splenocytes. Relative to control animals, ACD model mice exhibited increased expression of the Th17-specific transcription factor RORγt and decreased expression of the Treg-specific transcription factor Foxp3 at the mRNA level (P < 0.01, Figure 3). Following fisetin or CTX treatment, RORγt mRNA levels were substantially diminished, while Foxp3 levels were enhanced with respect to the ACD model group (P < 0.01).

3.5. Fisetin Modulates Cytokine Production in ACD Model Mice. Next, serum IL-17, IL-10, IL-6, TNF-α, and TGF-β levels in these ACD model mice were assessed via ELISA (Figure 4). Relative to controls, ACD model mice exhibited enhancements in TNF-α, IL-6, and IL-17 levels (P < 0.01), while TGF-β and IL-10 levels were significantly reduced in these ACD model mice (P < 0.05 or P < 0.01). Conversely, fisetin and CTX treatments reduced TNF-α, IL-6, and IL-17 levels (P < 0.05 or P < 0.01) while increasing TGF-β and IL-10 levels (P < 0.05 or P < 0.01). The obtained outcomes illuminate that fisetin is able to suppress inflammatory cytokine production while enhancing the secretion of anti-inflammatory cytokines.

---

Table 1: Primers employed for PCR.

| Primer   | Sequence                          |
|----------|-----------------------------------|
| Foxp3    | 5′-TTTACCTATGCCCCTTTATC-3′        |
|          | 5′-GTAGGGCAACATGGCAGTA-3′         |
| RORγt    | 5′-ACCTCCACTGCAGCTGTGTGTC-3′      |
|          | 5′-TCATTTCTGCACGTCACTGATAAGCTGTC-3′ |
| β-Actin  | 5′-CCCATCTATGAGGGTACGCC-3′        |
|          | 5′-TTAATGTCAACGACTTTC-3′          |
**Table 2:** The impact of FIS on Th17/Treg of ACD mice.

| Group         | Treg (%) | Th17 (%) | Th17/Treg (%) |
|---------------|----------|----------|---------------|
| Control       | 9.672 ± 0.781 | 0.581 ± 0.014 | 0.064 ± 0.013 |
| ACD           | 7.013 ± 0.269**  | 2.805 ± 0.293**  | 0.412 ± 0.016**  |
| CTX           | 8.201 ± 0.105**  | 1.394 ± 0.093**  | 0.175 ± 0.038**  |
| Fisetin 2 mg/kg | 7.828 ± 0.484*   | 2.739 ± 0.102   | 0.354 ± 0.023   |
| Fisetin 4 mg/kg | 8.565 ± 0.677**  | 1.799 ± 0.203**  | 0.219 ± 0.039**  |
| Fisetin 8 mg/kg | 9.283 ± 0.371**  | 1.272 ± 0.322**  | 0.143 ± 0.034**  |

Notes: **P < 0.01 vs. control group. *P < 0.05 and **P < 0.01 vs. ACD group.
4. Discussion

Allergic contact dermatitis is a relatively common form of allergic skin disease that can be triggered by sensitizing allergens which can be challenging to avoid in daily life. ACD treatment at present primarily relies on the use of H1 receptor antagonists and glucocorticoids, but these exhibit relatively limited efficacy and high rates of side effects [26–28], highlighting a need for the design of novel, safe treatments for this condition. Fisetin is a flavonoid compound present within a variety of plants, fruits, and vegetables [29, 30]. We have previously shown fisetin to suppress Th1/Th2 cell activities, and we herein sought to expand these analyses by assessing its ability to modulate Th17/Treg immunological homeostasis in a murine model of ACD [31, 32].

Repeated DNFB application successfully induced a model of ACD in our experimental mice characterized by pronounced ear swelling by 48 h post-DNFB application. Fisetin treatment was sufficient to alleviate such swelling, and these findings were further confirmed through histopathological analyses revealing that fisetin was able to reduce DNFB-induced epidermal inflammation and inflammatory cell infiltration.

CD4+ Th17 and Treg cells exhibit opposite performances in the regulation of autoimmune inflammation and the maintenance of immune homeostasis [33, 34]. Prior work suggests that excess Th17 cell activation and impaired Treg activity are correlated with the expansion of a range of autoimmune disorders. As such, modulating this Th17/Treg balance may effectively treat ACD [35, 36]. We thus explored the capability of fisetin for modulating the Th17/Treg balance in our ACD model mice. While ACD model animals exhibited increases in Th17 cells and decreased Treg cell levels relative to controls, fisetin and CTX treatment decreased Th17 cell frequencies and enhanced Treg cell frequencies. These data suggest that Th17/Treg cell imbalance is a hallmark of ACD that is amenable to fisetin-mediated immunomodulatory regulation.

RORγt and Foxp3 are lineage-specific regulatory transcription factors that control the function and differentiation of Treg and Th17 cells, respectively [37, 38]. To assess the ability of fisetin to alter the expression of these transcription factors, we examined Foxp3 and RORγt expression in ACD model mice, revealing that such treatment reduced decreased RORγt expression and enhanced Foxp3 expression. As such, these data support the existence of Th17/Treg imbalance in ACD model mice that was remediated by fisetin treatment.

Cytokines function as key regulators of the differentiation of Th17 and Treg subsets, with IL-6 and TGF-β modulating the expression of lineage-specific transcription factors within CD4+ cells in the context of such fate determination [39, 40]. Low TGF-β concentrations in the presence of IL-6 are able to drive the differentiation of Th17 cells and their

![Graphical representation of fisetin’s effect on RORγt and Foxp3 mRNA expression in vivo.](image.png)
Figure 4: Continued.
sequent secretion of IL-17A and TNF-α, which in turn promote local inflammation, whereas high TGF-β concentrations are capable of promoting the differentiation of Tregs [41, 42]. IL-10 is an anti-inflammatory cytokine that hinders inflammatory cell activation and proinflammatory cytokine secretion [43, 44]. Here, we found that fisetin treatment was associated with marked reductions in IL-17A, IL-6, and TNF-α treatment relative to the levels of these cytokines in ACD model mice, whereas the Treg-related cytokines IL-10 and TGF-β were present at high levels in fisetin-treated mice. This suggests that fisetin can suppress ACD-related disease pathology by enhancing anti-inflammatory IL-10 and TGF-β production while downregulating levels of inflammatory mediators including IL-17A, IL-6, and TNF-α.

Briefly, we herein employed a DNFB-induced murine ACD model system to demonstrate that fisetin treatment was sufficient to suppress ear swelling following DNFB treatment owing to its ability to inhibit the recruitment of inflammatory cells to the inflamed ear tissue section. Fisetin was also able to restore the Th17/Treg balance in these mice by inhibiting the secretion of IL-17, IL-6, and TNF-α and the expression of RORγt at the mRNA level while enhancing TGF-β and IL-10 secretion and promoting the mRNA-level upregulation of Foxp3. Fisetin may thus represent a viable candidate drug for ACD treatment owing to its ability to modulate the Th17/Treg balance.

**Data Availability**

The data used to support the findings of this study are available from the corresponding author upon request.

**Conflicts of Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to affect the investigation reported in this paper.

**Authors’ Contributions**

Bocui Song and Xue Shen performed the study conception and design. Min Liu and Qian Chen performed the data acquisition and analysis. Yuqi Li and Baolei Huang performed the interpretation of data. Mengmeng Jiang and Shuang Zhang drafted the manuscript. Rui Zhao and Yan-hong Wang revised the manuscript. Chenghao Jin and Chunyu Tong performed the final approval of the manuscript to be submitted.

**Acknowledgments**

This research was supported by the National Nature Science Foundation of China (31702289 and 31772789), the Post-doctoral Scientific Research Start-up Fund of Heilongjiang (LBH-Q21158), Heilongjiang Bayi Agricultural University’s scientific research start-up plan for learning and introducing talents (XYB2015-09), the Training Program for Youth Innovation Talents of Heilongjiang Educational Committee (UNPYSCT-2017), the Heilongjiang Bayi Agricultural University Support Program for “San Zong” (TDJH201905), and the College Students’ Innovation and Entrepreneurship Training Program in Heilongjiang Province: Inhibitory Effect of Gossypol on Eotaxin in IgE Mediated Type I Allergic Reaction Mice (201910223026).

**References**

[1] A. Herman, O. Aerts, L. de Montjoye, I. Tromme, A. Goossens, and M. Baek, "Isothiazolinone derivatives and allergic contact dermatitis: a review and update," *Journal of the European Academy of Dermatology and Venereology*, vol. 33, no. 2, pp. 267–276, 2019.

[2] M. G. Ahlström, J. P. Thyssen, M. Wennervaldt, T. Menné, and J. D. Johansen, "Nickel allergy and allergic contact dermatitis: a clinical review of immunology, epidemiology, exposure, and treatment," *Contact Dermatitis*, vol. 81, no. 4, pp. 227–241, 2019.

[3] A. Poppel, J. Williams, G. Maxwell, N. Gellatly, R. J. Dearman, and I. Kimber, "The lymphocyte transformation test in allergic
contact dermatitis: new opportunities,” Journal of Immunotoxicology, vol. 13, no. 1, pp. 84–91, 2016.

[4] Q. Xiang, Q. Yu, H. Wang et al., ”Immunomodulatory effect of _Ganoderma atrum_ polysaccharides on Th17/Treg balance,” Journal of Functional Foods, vol. 45, pp. 215–222, 2018.

[5] H. M. Knechelmann, C. J. Dwyer, S. R. Bailey et al., “When worlds collide: Th17 and Treg cells in cancer and autoimmune,” Cellular & Molecular Immunology, vol. 15, no. 5, pp. 458–469, 2018.

[6] J. Yang, X. Yang, H. Zou, Y. Chu, and M. Li, “Recovery of the immune balance between Th17 and regulatory T cells as a treatment for systemic lupus erythematosus,” Rheumatology, vol. 50, no. 8, pp. 1366–1372, 2011.

[7] S. A. Pandit and L. R. D. Glass, “Non-glaucoma periocular allergic, atopic, and irritant dermatitis at an academic institution: a retrospective review,” Orbit, vol. 38, no. 2, pp. 112–118, 2019.

[8] A. J. Hendricks, G. Yosipovitch, and V. Y. Shi, “Dupilumab use in dermatologic conditions beyond atopic dermatitis – a systematic review,” Journal of Dermatological Treatment, vol. 32, no. 1, pp. 219–230, 2021.

[9] R. R. Vatti, F. Ali, S. Teuber, C. Chang, and M. E. Gershwin, “Hypersensitivity reactions to corticosteroids,” Clinical Reviews in Allergy & Immunology, vol. 47, no. 1, pp. 26–37, 2014.

[10] L. Fonacier and I. Noor, “Contact dermatitis and patch testing for the allergist,” Annals of Allergy, Asthma & Immunology, vol. 120, no. 6, pp. 592–598, 2018.

[11] M. Aquino and G. Rosner, “Systemic contact dermatitis,” Clinical Reviews in Allergy & Immunology, vol. 56, no. 1, pp. 9–18, 2019.

[12] M. Imran, F. Saeed, S. A. Gilani et al., ”Fisetin: an anticancer perspective,” Food Science & Nutrition, vol. 9, no. 1, pp. 3–16, 2021.

[13] H. Sharif, M. S. H. Akash, K. Rehman, K. Irshad, and I. Imran, ”Pathophysiology of atherosclerosis: association of risk factors and treatment strategies using plant-based bioactive compounds,” Journal of Food Biochemistry, vol. 44, no. 11, article e13449, 2020.

[14] J. Das, R. Singh, and D. Sharma, ”Antiepileptic effect of fisetin in iron-induced experimental model of traumatic epilepsy in rats in the light of electrophysiological, biochemical, and behavioral observations,” Nutritional Neuroscience, vol. 20, no. 4, pp. 255–264, 2017.

[15] X. Zhao, C. Wang, W. G. Cui, Q. Ma, and W. H. Zhou, ”Fisetin exerts antihyperalgesic effect in a mouse model of neuropathic pain: engagement of spinal serotonergic system,” Scientific Reports, vol. 5, no. 1, pp. 1–12, 2015.

[16] X. Yao, L. Li, A. D. Kandhare, A. A. Mukherjee-Kandhare, and S. L. Bodhankar, ”Attenuation of reserpine-induced fibromyalgia via ROS and serotonergic pathway modulation by fisetin, a plant flavonoid polyphenol,” Experimental and Therapeutic Medicine, vol. 19, no. 2, pp. 1343–1355, 2020.

[17] P. Maher, T. Akaishi, and K. Abe, ”Flavonoid fisetin promotes ERK-dependent long-term potentiation and enhances memory,” Proceedings of the National Academy of Sciences, vol. 103, no. 44, pp. 16568–16573, 2006.

[18] T. H. Ying, S. F. Yang, S. J. Tsai et al., ”Fisetin induces apoptosis in human cervical cancer HeLa cells through ERK1/2-mediated activation of caspase-8/-caspase-3-dependent pathway,” Archives of Toxicology, vol. 86, no. 2, pp. 263–273, 2012.

[19] X. Sun, X. Ma, Q. Li et al., ”Anti-cancer effects of fisetin on mammary carcinoma cells via regulation of the PI3K/Akt/mTOR pathway: in vitro and in vivo studies,” International Journal of Molecular Medicine, vol. 42, no. 2, pp. 811–820, 2018.

[20] Y. Suh, F. Afaq, N. Khan, J. J. Johnson, F. H. Khusro, and H. Mukhtar, ”Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells,” Carcinogenesis, vol. 31, no. 8, pp. 1424–1433, 2010.

[21] N. Akhtar, S. A. A. Mohammed, R. A. Khan et al., ”Self-generating nano-emulsification techniques for alternatively-routed, bioavailability enhanced delivery, especially for anti-cancers, anti-diabetics, and miscellaneous drugs of natural, and synthetic origins,” Journal of Drug Delivery Science and Technology, vol. 58, article 101808, 2020.

[22] A. Roy, S. Saha, D. Roy, S. Bhattacharyya, and M. N. Roy, ”Formation & specification of host-guest inclusion complexes of an anti-malarial drug inside into cyclic oligosaccharides for enhancing bioavailability,” Journal of Inclusion Phenomena and Macrocyclic Chemistry, vol. 97, no. 1–2, pp. 65–76, 2020.

[23] S. C. Kim, S. H. Kang, S. J. Jeong, S. H. Kim, H. S. Ko, and S. H. Kim, ”Inhibition of c-Jun N-terminal kinase and nuclear factor κ B pathways mediates fisetin-exerted anti-inflammatory activity in lipopolysaccharide-treated RAW264.7 cells,” Immunopharmacology and Immunotoxicology, vol. 34, no. 4, pp. 645–650, 2012.

[24] J. Zhang, L. Zhao, C. Hu et al., ”Fisetin prevents acetaminophen-induced liver injury by promoting autophagy,” Frontiers in Pharmacology, vol. 11, p. 162, 2020.

[25] B. K. Maura and S. K. Trigun, ”Fisetin modulates antioxidant enzymes and inflammatory factors to inhibit aflatoxin-B1 induced hepatocellular carcinoma in rats,” Oxidative Medicine and Cellular Longevity, vol. 2016, 9 pages, 2016.

[26] J. I. Silverberg, ”Comorbidities and the impact of atopic dermatitis,” Annals of Allergy, Asthma & Immunology, vol. 123, no. 2, pp. 144–151, 2019.

[27] C. T. Robb, H. J. McSorley, J. Lee et al., ”Prostaglandin E2 stimulates adaptive IL-22 production and promotes allergic contact dermatitis,” Journal of Allergy and Clinical Immunology, vol. 141, no. 1, pp. 152–162, 2018.

[28] P. Gamradt, L. Laouibi, A. Noshbaum et al., ”Inhibitory checkpoint receptor control CD8+ resident memory T cells to prevent skin allergy,” Journal of Allergy and Clinical Immunology, vol. 143, no. 6, pp. 2147–2157.e9, 2019.

[29] G. Feng, Z. Jiang, B. Sun, J. Fu, and T. Z. Li, ”Fisetin alleviates lipopolysaccharide-induced acute lung injury via TLR4-mediated NF-xB signaling pathway in rats,” Inflammation, vol. 39, no. 1, pp. 148–157, 2016.

[30] B. Song, S. Guan, J. Lu et al., ”Suppressive effects of fisetin on mice T lymphocytes in vitro and in vivo,” Journal of Surgical Research, vol. 185, no. 1, pp. 399–409, 2013.

[31] A. Hosseini, S. Dolati, V. Hashemi, M. Abdollahpour-Alitappeh, and M. Youssefi, ”Regulatory T and T helper 17 cells: their roles in preeclampsia,” Journal of Cellular Physiology, vol. 233, no. 9, pp. 6561–6573, 2018.

[32] R. González-Amaro and M. Marazuela, ”T regulatory (Treg) and T helper 17 (Th17) lymphocytes in thyroid autoimmunity,” Endocrine, vol. 52, no. 1, pp. 30–38, 2016.

[33] A. Sarvari, J. A. Madrigal, and A. Saudemont, ”B cell regulation in cancer and anti-tumor immunity,” Cellular & Molecular Immunology, vol. 14, no. 8, pp. 662–674, 2017.
[34] M. Xu, X. Y. Duan, Q. Y. Chen et al., “Effect of compound sophorae decoction on dextran sodium sulfate (DSS)-induced colitis in mice by regulating Th17/Treg cell balance,” Biomedicine & Pharmacotherapy, vol. 109, pp. 2396–2408, 2019.

[35] T. Zhu, D. Zhou, Z. Zhang et al., “Analgesic and antipruritic effects of oxymatrine sustained-release microgel cream in a mouse model of inflammatory itch and pain,” European Journal of Pharmacetical Sciences, vol. 141, p. 105110, 2020.

[36] Q. Li, B. Wang, K. Mu, and J. A. Zhang, “The pathogenesis of thyroid autoimmune diseases: new T lymphocyte–cytokines circuits beyond the Th1–Th2 paradigm,” Journal of Cellular Physiology, vol. 234, no. 3, pp. 2204–2216, 2019.

[37] A. N. Kamali, S. M. Noorbakhsh, H. Hamedifar et al., “A role for Th1-like Th17 cells in the pathogenesis of inflammatory and autoimmune disorders,” Molecular Immunology, vol. 105, pp. 107–115, 2019.

[38] E. Cretney, A. Kallies, and S. L. Nutt, “Differentiation and function of Foxp3+ effector regulatory T cells,” Trends in Immunology, vol. 34, no. 2, pp. 74–80, 2013.

[39] C. Saini, R. K. Srivastava, M. Tarique et al., “Elevated IL-6R on CD4+ T cells promotes IL-6 driven Th17 cell responses in patients with T1R leprosy reactions,” Scientific Reports, vol. 10, no. 1, pp. 1–13, 2020.

[40] S. Zhang, “The role of transforming growth factor β in T helper 17 differentiation,” Immunology, vol. 155, no. 1, pp. 24–35, 2018.

[41] D. Wang, S. Huang, X. Yuan et al., “The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus,” Cellular & Molecular Immunology, vol. 14, no. 5, pp. 423–431, 2017.

[42] K. K. Chang, L. B. Liu, L. P. Jin et al., “IL-27 triggers IL-10 production in Th17 cells via a c-Maf/RORγt/Blimp-1 signal to promote the progression of endometriosis,” Cell Death & Disease, vol. 8, no. 3, pp. e2666–e2666, 2017.

[43] M. Boshtam, S. Asgary, S. Kouhpayeh, L. Shariati, and H. Khanahmad, “Aptamers against pro- and anti-inflammatory cytokines: a review,” Inflammation, vol. 40, no. 1, pp. 340–349, 2017.

[44] J. Park, J. T. Decker, D. J. Margul et al., “Local immunomodulation with anti-inflammatory cytokine-encoding lentivirus enhances functional recovery after spinal cord injury,” Molecular Therapy, vol. 26, no. 7, pp. 1756–1770, 2018.